Furadonin tablets 100mg №10×2

Name Furadonin tabl. The main active ingredient Nitrofurantoin Release form tablets Dosage 50 mg Pharmacological properties Pharmacodynamics Synthetic antimicrobial agent with a wide spectrum of action. Acts bactericidal. The mechanism of action is associated with the reduction of furadonin into an active intermediate that damages ribosomal proteins and disrupts protein, DNA, and RNA synthesis. In high doses, it disrupts the permeability of the bacterial cell membrane. Active against gram-positive aerobic bacteria: Staphylococcus spp., Streptococcus spp.; gram-negative aerobic bacteria: Escherichia coli, Enterobacter spp., Klebsiella spp., Shigella spp. Weakly active against Enterococcus spp., fungi of the genus Candida. Not active against Pseudomonas aeruginosa, Acinetobacter spp. Most strains of Proteus and Serratia are resistant to furadonin. Pharmacokinetics Furadonin is well absorbed in the upper gastrointestinal tract and rapidly excreted in the urine. The half-life is about 30 minutes. The maximum excretion in the urine occurs 2-4 hours after taking furadonin, the proportion of unchanged drug is about 40-45%. Indications for use: uncomplicated urinary tract infections (cystitis, urethritis, pyelitis) caused by susceptible microorganisms; prevention of infections during urological operations and examinations (cystoscopy, catheterization). Adult patients Acute uncomplicated urinary tract infections: 50 mg four times a day for seven days. Severe reinfection: 100 mg four times a day for seven days. Long-term maintenance therapy: 50-100 mg once a day. Prevention: 50 mg four times a day for urological operations and examinations and 3 days after them. Children over 6 years Acute uncomplicated urinary tract infections: 3 mg/kg/day in four divided doses for seven days. Maintenance therapy: 1 mg/kg once a day. For children weighing less than 25 kg, the use of the drug in the form of a suspension is recommended. Use during pregnancy and lactation The use of furadonin during pregnancy is contraindicated. If it is necessary to use it during lactation, the child should be weaned from the breast for the entire period of treatment. Precautions The drug should be discontinued at the first signs of peripheral neuropathy (the occurrence of paresthesias), because. development of this complication can be life-threatening. It is necessary to stop treatment with furadonin if unexplained symptoms of impaired function of the lungs, liver, hematological and neurological disorders occur. In the event of signs of lung damage, furadonin should be discontinued immediately. Careful monitoring of lung function is necessary in patients receiving long-term treatment with furadonin, especially in the elderly. Careful monitoring of patients receiving long-term therapy with furadonin is necessary in order to identify signs of the development of hepatitis. After taking furadonin, urine may turn yellow or brown. In patients receiving furadonin, false positive reactions may occur when determining glucose in the urine. Furadonin should be discontinued if there are signs of hemolysis in patients with suspected glucose-6-phosphate dehydrogenase deficiency. Reactions from the gastrointestinal tract can be minimized when taking the drug with food, milk, or by reducing the dose. With prolonged therapy, the development of superinfection caused by fungi or insensitive microorganisms is possible. Nitrofurantoin should be used with caution in case of impaired renal function (creatinine clearance 60-90 ml / min), suspected deficiency of glucose-6-phosphate dehydrogenase or other erythrocyte enzymes, in debilitated patients, people with allergies, liver pathology, lungs, neurological disorders. Interaction with other drugs The absorption of furadonin increases when taken with food or together with drugs that cause delayed gastric emptying. Magnesium trisilicate reduces the absorption of furadonin. Probenecid and sulfinpyrazone reduce the renal excretion of furadonin. Carbonic anhydrase inhibitors and agents that cause an alkaline reaction of urine reduce the antibacterial activity of furadonin. Furadonin and antimicrobial agents from the group of fluoroquinolones are antibacterial antagonists. Furadonin can suppress intestinal flora, which leads to a decrease in estrogen absorption and the effectiveness of estrogen-containing contraceptives. Patients are advised to use non-hormonal methods of contraception. Furadonin can inactivate oral typhoid vaccine. Contraindications hypersensitivity to nitrofurantoin or nitrofurans; severe renal dysfunction, renal failure, oliguria (creatine clearance less than 60 ml / min); children under 6 years of age, pregnancy, and lactation due to possible hemolytic anemia in the fetus or newborn due to with immaturity of erythrocyte enzyme systems; cirrhosis of the liver, chronic hepatitis; chronic heart failure (III-IV class according to NYHA); insufficiency of glucose-6-phosphate dehydrogenase; acute porphyria. Composition One tablet contains: active ingredient: nitrofurantoin 50 mg or 100 mg; excipients: potato starch, anhydrous colloidal silicon dioxide, calcium stearate. OverdoseSymptoms: with the introduction of high doses, dizziness, nausea, and vomiting may occur. Treatment: withdrawal of the drug, taking a large amount of fluid to increase the excretion of the drug in the urine, hemodialysis, symptomatic therapy. There is no specific antidote. Side effects From the gastrointestinal tract: nausea, vomiting, lack of appetite, abdominal pain, diarrhea, pancreatitis, pseudomembranous colitis. From the side of the liver and biliary tract: cholestatic jaundice, cholestatic syndrome, chronic active hepatitis (sometimes fatal, usually with long-term therapy). If symptoms of hepatotoxicity appear, the drug should be discontinued. From the nervous system: headache, drowsiness, dizziness, depression, euphoria, nystagmus, confusion, psychotic reactions, intracranial hypertension. In rare cases, severe and even irreversible peripheral neuropathy (including damage to the optic nerve) with symptoms of sensory and motor disorders. With these symptoms, the drug should be discontinued. From the respiratory system: acute pulmonary reactions (usually develop during the first week of treatment and are reversible after discontinuation of the drug) are characterized by the sudden onset of fever, eosinophilia, cough, chest pain, shortness of breath, the formation of pulmonary infiltrate, pleural effusion. Chronic pulmonary reactions are rare, in patients who have received long-term therapy for 6 months or more, more often in elderly patients. The severity depends on the duration of treatment after the first clinical symptoms. There may be changes in the ECG associated with pulmonary reactions, rarely – cyanosis, collapse. Impaired lung function may be irreversible. When the first signs of a violation of the respiratory system appear, the drug should be discontinued. From the skin and subcutaneous tissue: hypersensitivity reactions – skin rashes, maculopapular rash, urticaria, itching in some cases: angioedema, anaphylaxis, inflammation of the salivary glands, eczema, exfoliative dermatitis, erythema multiforme (including Stevens-Johnson syndrome), lupus-like syndrome . From the hematopoietic and lymphatic systems: leukopenia, granulocytopenia or agranulocytosis, thrombocytopenia, megaloblastic anemia, aplastic anemia, hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency. From the musculoskeletal system: arthralgia. Others: reversible alopecia, superinfection (often caused by Pseudomonas aeruginosa or fungi), urine staining dark yellow or brown. Storage conditions In a place protected from light and moisture, at a temperature not exceeding 25? Keep out of the reach of children. Buy Furadonin tablets 100mg No. 10×2 The price of Furadonin tablets 100mg No. 10×2